Effectiveness of hipertonic saline serum 3% nebulized in bronchiolitis - EMABRHIP

Fundacion par la investigación biomédica del Hospital Universitario La Paz0 个研究点开始时间: 2012年2月29日最近更新: 2013年3月4日

适应症

试验速览

暂无简介。

•Age between 7 days and 6 months.
•Diagnosis of moderate-serious bronchiolitis (first episode of wheezing lower respiratory difficulty in the context of the upper airways viral infection ) which require hospital admission in participating sites(Score Wood-Downes modified between 4-7).
•Informed consent from Parents or guardians according to the current legislation on clinical research (Declaration of Helsinki, Law 14/2007 of 3 July biomedical research)
•Are the trial subjects under 18? yes
•Number of subjects for this age range: 130
•F.1.2 Adults (18-64 years) no
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•Severe bronchiolitis requiring ventilation or admission to ICU when the patient has an oxygen saturation <94 with oxygen supply> 2l/min, a Score = 8 and / or PaCO2 = 65 mmHg, assessing the indication for assisted ventilation (high-flow systems, C-PAP, ventilation invasive mechanical) and / or transfer to the Pediatric Intensive Care Unit with the practice of each hospital.
•Cardiac or pulmonary disease base.
•Previous diagnosis of asthma.
•Use of bronchodilators.
•Need for cardiopulmonary resuscitation.
•Inability to use nebulizer.
•Concomitant use of antibiotics.
•Use of corticosteroids.
•No informed consent.
•Prescribed treatment with nebulized epinephrine

发起方

Fundacion par la investigación biomédica del Hospital Universitario La Paz